CM-PRP-HA has an excellent safety profile in clinical practice.1,3,4
Cellular Matrix® technology combines the complementary clinical effects of RegenPRP® and hyaluronic acid (HA), giving better and longer-lasting results in patients with osteoarthritis.1,3,4
Hyaluronic acid is a major component of synovial fluid contributing to joint homeostasis.
Hyaluronic acid improves the activity of several molecules contained in platelet-rich plasma to provide additional benefits to OA patients1.
Both PRP and HA have been extensively used to improve lubrication, modulate inflammation and modify the joint catabolic micro-environment, aiming not only to reduce clinical symptoms, but also to slow down OA progression2.
When PRP and HA are used in combination these effects are enhanced and prolonged. HA creates a bioactive scaffolding in which the platelets progressively release their growth factors. RegenPRP does not negatively affect the mechanical, elastic or viscous properties of HA1.
The simple, safe and efficient point-of-care preparation of autologous platelet-rich plasma.
~3 ml of PRP combined with 2 ml of HA
> 70 %